Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
Authors
- Michael A. Carducci (ORCID: https://orcid.org/0000-0002-7908-1215)
- Scott T. Tagawa (ORCID: https://orcid.org/0000-0003-2777-8587)
- David S. Morris (ORCID: https://orcid.org/0000-0003-2120-4590)
- Andrei Iagaru (ORCID: https://orcid.org/0000-0003-0839-5329)
- Charles J. Ryan (ORCID: https://orcid.org/0000-0002-2081-3557)
- Michael J. Morris (ORCID: https://orcid.org/0000-0002-9454-0096)
- Emmanuel S. Antonarakis (ORCID: https://orcid.org/0000-0003-0031-9655)
- Neeraj Agarwal
- E. David Crawford (ORCID: https://orcid.org/0000-0002-5009-1655)
- Mary‐Ellen Taplin (ORCID: https://orcid.org/0000-0002-3384-0300)
- Jérémie Calais (ORCID: https://orcid.org/0000-0002-8839-4379)
- Alan Haruo Bryce (ORCID: https://orcid.org/0000-0002-0206-3895)
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Scott B. Sellinger
- Maha Hussain (ORCID: https://orcid.org/0000-0003-0380-9465)
- Matthew B. Rettig (ORCID: https://orcid.org/0000-0002-7394-3056)
- Himisha Beltran (ORCID: https://orcid.org/0000-0003-3259-2226)
- Jason A. Efstathiou (ORCID: https://orcid.org/0000-0003-0996-0350)
- Daniel Peter Petrylak (ORCID: https://orcid.org/0000-0001-6165-5797)
- Phillip J. Koo (ORCID: https://orcid.org/0000-0002-5375-3773)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Martin Gleave (ORCID: https://orcid.org/0000-0003-4235-0167)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Leonard G. Gomella (ORCID: https://orcid.org/0000-0002-9466-489X)
- Thomas A. Hope (ORCID: https://orcid.org/0000-0002-2228-5823)
- Oliver A. Sartor (ORCID: https://orcid.org/0000-0002-8777-7343)
- Daniel Eidelberg Spratt (ORCID: https://orcid.org/0000-0002-5973-4741)
- Celestia Higano
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Tanya Barauskas Dorff (ORCID: https://orcid.org/0000-0001-5990-298X)
- Tian Zhang (ORCID: https://orcid.org/0000-0001-8914-3531)
- Sandy Srinivas
- Robert E. Reiter
- Evan Yi-Wen Yu (ORCID: https://orcid.org/0000-0001-7825-5087)
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- City Of Hope National Medical Center (US)
- University of Minnesota (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- University of British Columbia (CA)
- Thomas Jefferson University (US)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- University of Washington (US)
- Cornell University (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- WinnMed (US)
- University of California System (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Urology Associates (US)
- Sidney Kimmel Cancer Center (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Yale New Haven Health System (US)
- University Hospitals Seidman Cancer Center (US)
- Stanford Medicine (US)
- Molecular Theranostics (United States) (US)
- VA Greater Los Angeles Healthcare System (US)
- Carolina Urologic Research Center (US)
- Weill Cornell Medicine (US)
- Banner MD Anderson Cancer Center
- Duke Cancer Institute
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cncr.35612
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- U.S. Department of Defense
- AstraZeneca
- Bayer HealthCare
- National Cancer Institute